There are no approved treatment options for patients with advanced bladder cancer after they’ve received standard chemotherapy and immune treatments, but the results of a phase II clinical trial led by Yale Cancer Center and Smilow Cancer Hospital...
Yale Cancer Center scientists have built a powerful genomic research platform to study cervical cancer, a disease that often is untreatable if it progresses after surgery or primary chemo-radiation treatment. The work is described in a study published...
The checkpoint inhibitor pembrolizumab (Keytruda) increases the survival time of patients with advanced head and neck cancers, according to a new global study led by Yale Cancer Center (YCC). The data was published today in the journal The Lancet.
The...
According to the results of a large, global study led by Yale Cancer Center researchers, even a tiny amount of a biomarker known as PD-L1 (programmed death-ligand1) can predict a long-term survival benefit from using pembrolizumab (Keytruda). The drug is...
Lung cancer spreads to the brain in about one-quarter of patients with an advanced form of the disease. To date, radiation has been the only treatment option, but it comes with toxic side effects. Researchers at Yale Cancer Center (YCC) have found that...
In a new Yale Cancer Center (YCC) study, researchers have demonstrated that a higher percentage of women with breast cancer had their disease diagnosed at an early stage in states with expanded Medicaid coverage through the Affordable Care Act (ACA). No...